As More Products Get Priority Review, User Fee Cost Gap From Standard Review Is Narrowing

 
• By Derrick Gingery
  
Priority seats
The FDA has been conducting an increasing number of priority assessments of NME NDAs and BLAs in recent years. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from User Fees

More from Pathways & Standards